Product vs. Platform With Surface's Vito Palombella, Ph.D. and Robert Ross, M.D.
Business Of Biotech · 63 minutes ·

Product vs. Platform With Surface's Vito Palombella, Ph.D. and Robert Ross, M.D.

Earlier this month, Surface Oncology shared that it will open a second stage of its monotherapy trial of SRF388, an antibody targeting IL-27, on the heels of a promising phase 2 data readout. Shortly before that release, the Business of Biotech caught up with Surface's CSO Vito Palombella, Ph.D. and CEO Rob Ross, M.D. in the company's Cambridge, MA HQ. We discussed the first-of-its-kind target, the company's "product versus platform" strategy and how it fits in the industry's current "platform" vibe, the finer points of building and maintaining a startup bio culture, the difference between that Bob Ross and the Rob Ross, M.D., and whole lot more. 


Comments (0)

You Must Be Logged In To Comment

Similar podcasts

Ross Files with Dave Ross

Ross Copperman vs Guy Chambers part 2

Beautiful and Bothered with Johnny Ross

3AW Breakfast with Ross and Russel

Foodist with Darya Rose, Ph.D

Freakonomics, M.D.

Earth Speak with Natalie Ross and Friends